TG Therapeutics, Inc. (TGTX) Debt by Year
TG Therapeutics, Inc. carried $245.6M in long-term debt against $79.1M in cash and equivalents at the end of fiscal year 2025. This represents an increase of 0.5% from the prior fiscal year. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters TG Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
TGTX Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $245.6M+0.5% | $244.4M+144.1% | $100.1M+40.7% | $71.1M+6.5% | $66.8M+765.6% | $7.7M-73.4% | $29.0M | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $79.1M-56.0% | $179.9M+93.6% | $92.9M-9.2% | $102.3M-65.8% | $298.9M-46.0% | $553.4M+391.3% | $112.6M+168.5% | $42.0M-26.0% | $56.7M+126.6% | $25.0M-54.5% | $55.1M-1.2% | $55.7M+37.6% | $40.5M+146.0% | $16.5M+68.8% | $9.7M |
TGTX Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $745.4M+204.2% | $745.1M+204.5% | $245.6M+0.5% | $245.3M+0.5% | $245.0M+139.0% | $244.7M+141.5% | $244.4M+144.1% | $244.2M+146.9% | $102.5M+5.0% | $101.3M+5.0% | $100.1M+40.7% | $98.9M+39.0% |
| Cash & Equivalents | $482.6M+273.7% | $442.2M+234.7% | $79.1M-56.0% | $74.1M-62.2% | $129.1M+55.7% | $132.1M+75.1% | $179.9M+93.6% | $195.8M+29.8% | $82.9M-14.5% | $75.5M+22.8% | $92.9M-9.2% | $150.9M+37.4% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More TG Therapeutics, Inc. financials
Frequently Asked Questions
What was TG Therapeutics, Inc.'s long-term debt in fiscal year 2025?
TG Therapeutics, Inc. carried $245.6M in long-term debt against $79.1M in cash and equivalents at the end of fiscal year 2025.
How fast is TG Therapeutics, Inc.'s long-term debt growing?
TG Therapeutics, Inc. (TGTX) long-term debt rose by 0.5% year over year, from $244.4M to $245.6M in fiscal year 2025.
What was TG Therapeutics, Inc.'s long-term debt in the most recent quarter?
TG Therapeutics, Inc. (TGTX) reported $745.4M in long-term debt in Q2 2026. This represents an increase of 204.2% from the same quarter a year earlier.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what TG Therapeutics, Inc. (TGTX) reported on that line in every period on record.